Mylan NV has received FTC approval for its $7.2 billion purchase of Swedish rival Meda, under the condition that Mylan divests rights to two generic drugs.
The FTC said the deal could threaten the market for carisoprodol tablets, which treat muscle spasms and stiffness. Per FTC orders, Mylan will relinquish its U.S. marketing rights for the drug, allowing the drug’s maker Indicus Pharma to “compete independently in the U.S. market.”
FTC approval was the final regulatory step needed to complete the Medadeal, following approval by the European Commission a week ago with the requirement of several asset sales in various European countries.
Full Content: Marketwatch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI